DLL4 Matched ELISA Antibody Pair Set,Mouse

1/1
Price:
Size:
Number:

DLL4 Matched ELISA Antibody Pair Set,Mouse General Information

Product name
DLL4 Matched ELISA Antibody Pair Set,Mouse
Assay type
Solid Phase Sandwich ELISA
Specificity
Quantitative determination of Mouse DLL4
Assay range
9.38-600 pg/mL
Materials provided
1. Capture Antibody 1.0 mg/mL of rabbit anti-mouse DLL4 monoclonal antibody. Dilute to a working concentration of 2.0 μg/mL in CBS before coating. (Catalog: # 50640-R004)
2. Detection Antibody 0.25 mg/mL rabbit anti-mouse DLL4 polyclonal antibody conjugated to horseradish-peroxidase (HRP). Dilute to working concentration of 0.5 μg/mL in detection antibody dilution buffer before use.
3. Standard Each vial contains 25 ng of recombinant mouse DLL4. Reconstitute standard powder with 1 mL detection antibody dilution buffer. After reconstitution, store at -20℃ to -80℃ in a manual defrost freezer. A seven-point standard curve usi ng 2-fold serial dilutions in sample dilution buffer, and a high standard of 600 pg/mL is recommended.
Product overview
This DLL4 Matched ELISA Antibody Pair Set,Mouse is a solid phase sandwich ELISA for quantitative determination of Mouse DLL4 . It contains Mouse DLL4 capture antibody, Mouse DLL4 detector antibody (HRP) and a highly purified HEK293-expressed recombinant Mouse DLL4 protein. This Pair Set is at affordable price for researchers.
Shipping
This Matched ELISA Antibody Pair Set is shipped at ambient temperature.
Storage
Capture Antibody: Aliquot and store at -20℃ to -80℃ for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Detection Antibody: Protect it from prolonged exposure to light. Aliquot and store at -20℃ to -80℃ and for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Standard: Store lyophilized standard at -20℃ to -80℃ for up to 6 months from date of receipt. Aliquot and store the reconstituted Standard at -80℃ for up to 1 month. Avoid repeated freeze-thaw cycles.

DLL4 Matched ELISA Antibody Pair Set,Mouse Images

DLL4 Matched ELISA Antibody Pair Set,Mouse: Alternative Names

Delta4 Matched ELISA Antibody Pair Set, Mouse

DLL4 Background Information

Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
Full Name
delta-like 4 (Drosophila)
References
  • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
  • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
  • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
  • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait